Tobacco continues to be widely used world-wide, primarily via cigarette smoking, and is the leading cause of preventable deaths in the United States. Tobacco use is driven by nicotine addiction, which starts by nicotine binding to high-affinity nicotine binding sites in brain. 80-90% of the high-affinity sites are located on ?4?2-type nicotinic acetylcholine receptors (?4?2Rs). Prolonged nicotine exposure increases high-affinity ?4?2R binding sites in brain, a process termed ?upregulation?, linked to craving and withdrawal in nicotine addiction. This proposal is based on our recent discovery that ?4?2R ligands that are weak bases, such as the smoking cessation reagent varenicline (Chantix), can be selectively trapped in ?4?2R-containing acidic vesicles of cells and neurons. Slow release of trapped varenicline reduces the effects of nicotine upregulation. Selective trapping is further regulated by nicotine upregulation, which increases the numbers of ?4?2R-containing acidic vesicles. Nicotine, also a weak base, is not trapped because its ligand pKa and affinity for ?4?2Rs is lower than that of varenicline. These results provide a new paradigm for how varenicline causes smoking cessation. They also provide new information about the potential cellular distribution of??4?2R PET probes, all of which are weak bases. Like varenicline and nicotine, different ?4?2R PET probes have different ligand pKas and affinities for ?4?2Rs, which explains differences in kinetics, displaceable binding by varenicline and nicotine, non-displaceable binding and metabolism. While a number of studies have used PET probes specific for ?4?2R high-affinity binding sites in brain, these studies are complicated by the interpretations of the binding and binding kinetics especially when nicotine and/or varenicline are present. Using our concept about the trapping of ?4?2R weak base ligands in intracellular acidic vesicles, we will develop new cellular and whole models of PET probe kinetics that take into account ?4?2R ligand trapping in acidic vesicles. There is the potential of wider application of the PET methods that will be developed in this application, since for ?4?2R PET imaging is currently underway in a number of brain disorders. The goals of this proposal are to examine how our discovery of the trapping of weak base ?4?2R ligands in acid vesicles affects the imaging of ?4?2Rs using PET probes and to use PET probe imaging to examine how nicotine causes ?4?2R upregulation and how varenicline alters upregulation.

Public Health Relevance

Tobacco smoking is a leading cause of preventable deaths worldwide. It would be tremendously beneficial to understand why nicotine, in tobacco smoke, is highly addictive and to identify the mechanisms underlying addiction. The goals of our proposal are to better understand how positron emission tomography (PET) probes used to examine nicotine addiction are distributed at the cellular level and how this can be used to better assay different measures of nicotine addiction and smoking cessation.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA044760-01
Application #
9403663
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Pariyadath, Vani
Project Start
2017-07-01
Project End
2022-04-30
Budget Start
2017-07-01
Budget End
2018-04-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Chicago
Department
Biology
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Samra, Gurleen K; Intskirveli, Irakli; Govind, Anitha P et al. (2017) Development of fluorescence imaging probes for nicotinic acetylcholine ?4?2? receptors. Bioorg Med Chem Lett :